4SC provides headline results from Yakult Honsha's Phase II trial of resminostat in combination with sorafenib as first line therapy in liver cancer
4SC AG (4SC, FSE Prime Standard: VSC) today announced that its Japanese partner Yakult Honsha Co., Ltd. (Yakult Honsha)…